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Table 1
Immune and Clinical Parameters
Standard group
(N¼23)
Study group
(N¼14)
Med (range) Median (range)
CD 34+ cells collected (x 10^6/kg) 11.7 (5.1 - 20.7) 13.0 (10.1 -28.0)
CD 34+ cells infused (x 10^6/kg) 5.0 (3.2 - 8.3) 9.7 (7.0 e 14.0)
Duration of ANC < 500 k/mL
(days)
4 (3 - 9) 4 (3 - 5)
Time to neutrophil engraftment
(days)
10 (8 - 14) 10 (9 - 11)
Duration of ALC< 500 k/mL (days) 14 (5 - 22) 14 (12 - 23)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193S192existing bone marrow neuropathy may impair G-CSF driven
HSCmobilization and/or time to engrafment in the context of
ASCT for lymphoma. We retrospectively identiﬁed 46 ASCT
patients, all of whom were mobilized with G-CSF. Twenty
four patients were identiﬁed as poor mobilizers (PM) based
on the need for rescue pleriaxfor after mobilization failure,
while 22 patients were identiﬁed as good mobilizers (GM)
based on the ability to collect the target HSC dose within two
days of apheresis. We compared the clinical and immuno-
histochemical characteristics between the two groups. The
adequacy of bone marrow innervation was determined by
semiquantitative immunohistochemistical scoring of tyro-
sine hydroxylase positive (TH+) nerve terminals in pre-ASCT
bone marrow core biopsies. The mean TH scores were 2.33
for PM vs. 1.32 for GM (p¼0.2). There was a non signiﬁcant
trend towards a longer time to neutrophil/platelet engraft-
ment when no TH+ nerve terminals were identiﬁed vs. any
TH+ terminals identiﬁed (11/11.4 vs.10.8/10.7 days respec-
tively). HSC from the group with no TH+ nerve terminals had
less colony forming units (CFU) compared to the group that
had any TH+ terminals identiﬁed (7.1 vs. 10.4 x 106 CFU/kg, P
¼ .58). Also, the group with no TH+ nerve terminals had
lower peripheral blood CD34+ cell counts, before collection
and after G-CSF priming, compared to the group with any
TH+ terminals identiﬁed (18.3 vs. 28.7/mm3, P ¼ .66). As
expected, the time to neutrophil/platelet engrafment was
higher in the PM compared to the GM group (11.5/13.3 vs.
10.3/8.6, P ¼ .004/P < 0.0001, respectively). Owing to the
small sample size, we can't draw deﬁnite conclusions about
the impact of bone marrow neuropathy on HSC mobilization
and ASCT outcomes but we observed a trend toward higher
HSC mobilization, longer time to engraftment and decreased
HSC CFU capacity in patients with evidence of bone marrow
neuropathy. This is consistent with what other investigators
have demonstrated in animal models. Failure of G-CSF
mobilization was associated with longer time to neutrophil
and platelet engraftment in patients with lymphoma
undergoing ASCT.Time to lymphocyte engraftment
(days)
14 (9-21) 13 (11-22)
Time to PLT engraftment (days) 13 (0-17) 13.5 (10-20)
# of RBC Transfusions 0 (0 - 8) 0 (0 - 3)
# of PLT Transfusions 2 (0 - 12) 1 (1 - 4)
Days of T  38 deg C 1 (0-8) 0 (0-7)
Days on empiric/directed
antibiotics
5 (0 - 28) 0 (0 - 14)
Infections, N (%) 7 (30) 1 (7)
Days of diarrhea  500cc 0 (0-3) 0 (0-7)
Pts with ES, N (%) 0 (0) 3 (21)
Pts with infusion reactions, N (%) 2 (9) 0
Duration of hospitalization (days) 17 (13 - 36) 15 (13 - 19)157
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Background: High dose MEL with auto SCT is an established
therapeutic modality for MM. Although effective, it is associ-
ated with signiﬁcant symptom burden due to the obligate
periodofneutropeniaand increased riskof infection. Inanimal
models, infusing stemcells (SC) overa periodof days enhances
immune reconstitution (Felﬂy H, et al. 2009). Multiple SC
infusions could reduce the period of neutropenia and enhance
immune recovery resulting in a better tolerated procedure.
Methods: We are conducting a phase II trial of multiple
fractionated auto SC infusions after high-dose MEL. We
compared initial engraftment kinetics after high-doseMEL of
the ﬁrst 14 pts to receive multiple infusions (Days 0, +2, +4,+6) (study group) to 23 pts receiving the standard single SC
infusion (Day 0) (standard group). Pegﬁlgrastimwas given on
Day +1 and SCT was between October 2011 and July 2012 in
all pts.
Results: Table 1. Similar numbers of SCs were collected in
both groups. The number of SCs infused was 9.7 x 10^6
CD34+ cells/kg vs 5.0 x 10^6 CD34+ cells/kg in study and
standard pts. To date, the median duration of neutropenia
(days ANC < 500) and lymphopenia (days ALC < 500), and
days to neutrophil, lymphocyte and PLT engraftment were
similar. There were no signiﬁcant differences in the
number of red cell or PLT transfusions, days of fever,
diarrhea, empiric antibiotics or documented infections.
Despite multiple SC infusions, none of the pts in the study
group experienced infusion reaction. Engraftment
syndrome (ES) occurred in 3/14 of study pts. Duration of
hospitalization was 15 days in study pts vs 17 days in the
concurrent control group (P ¼ 0.01).
Conclusions:Multiple SC infusions after high doseMEL inpts
with MM were not associated with increased adverse effects
from DMSO or unexpected frequency of ES. Fractionating SCs
over a period of daysmay result in less antibiotic use, reduced
infection and was associated with shorter hospital stay. We
continue to collect pt reported symptom scores to determine
if we can improve pt experience during SCT.158
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S193Background: Use CXCR4 inhibitor Plerixafor for autologous
hematopoietic progenitor cell (HPC) mobilization in
myeloma (MM) and lymphoma has been associated with
reduction of mobilization failure. However, poor mobiliza-
tion (mobilopathy) still results in multiple days of collection,
increased resource utilization, morbidity and overall lower
numbers of HPCs. Mobilopathy is associated with exposure
to some chemotherapeutic agents, older age and female sex.
Ferraro et al recently postulated a diabetes-associated
mobilopathy. We analyzed mobilization patterns in a retro-
spective cohort of 221 patients undergoing mobilization
prior to autologous transplantation for MM (136) or
lymphoma (84).
Methods: Our algorithm for mobilization: A rescue (“just in
time”) plerixafor strategy was used after daily GCSF 10ug/kg
x5 days in those failing to develop adequate (<10
/uLCD34+HPC in peripheral blood (n¼8) or failing to mobi-
lize 1e6 CD34+HPC/kg on day 1of collection (n¼34). For
those predicted to be poor mobilizers based on prior mye-
lotoxic therapy or low platelet counts, 2 strategies were used
- planned Plerixafor after 5 days of GCSF or chemotherapy
followed by GCSF for those with no insurance coverage for
plerixafor.
Only 2 pts (<1%) failed to collect > 2e6 CD34+HPC/kg.
Major outcomes of interest for the remaining 219 pts were:
Collection of >2e6 CD34+HPC/kg on day1 and total CD
34+HPC collected over entire collection episode. Multivariate
regression models were used to evaluate potential predictors
of poormobilization. Diabetes requiring drug therapy (n¼32)
was considered in all models.
Results: Majority (75%) pts collected >2e6 CD34+HPC/kg on
day1. Among the 32 pts with diabetes, inadequate day 1
mobilization occurred in 40% (13/32) compared to 21% (40/
187) without diabetes. The use of HyperCVAD chemotherapy
was associated in 50% cases with inadequate CD34+HPC on
day1. In multivariate models, successful mobilization on
day1 was associated with absence of diabetes (odds ratio
2.49, P ¼ .04) and lack of HyperCVAD exposure (odds ratio
4.14, P ¼ .02).
Interestingly, although a signiﬁcant number received
“just in time” plerixafor, its use improved the total
CD34+HPC collection signiﬁcantly (odds ratio 2.98, 95% CI
P ¼ .0038) in all pts including 12 diabetic recipients.
In multivariate analysis, lower total yield of CD34+HPC/kg
was associated with increasing age (P¼0.0002) and the use
of conventional chemotherapy.
Conclusions: In our analysis of an unselected cohort of pts
undergoing mobilization, diabetes was an independent
predictor of slower mobilizationwith its effects mitigated by
plerixafor.
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Background: Health care institutions are identifying strate-
gies to reduce unnecessary testing, employ better utilization
of resources, and decrease patient risk. Both NCCN and IDSA
guidelines recommend reserving CXR for febrile neutropenic
(F+N) patients with respiratory symptoms. A retrospectivereview from 2010 showed that 11 of 237 (4.6%) Non Hodg-
kins Lymphoma and Multiple Myeloma SCT patients had
respiratory signs or symptoms when they presented with
F+N. Despite national guidelines, 97 of 237 (41%) patients
without symptoms also had a CXRwhen they presented with
F+N. None of the CXR in asymptomatic patients showed an
active pulmonary process. Based on these results and in
accordance with nationally recognized guidelines, we aimed
to reduce CXR in asymptomatic autologous F+N patients to
less than 10%.
Methods: A series of education sessions with clinical staff
including MDs, PAs, nocturnists and moonlighters were
implemented. Both oral andwrittenmaterials were prepared
for pass-off between the PAs and nocturnists. Study Pop-
ulation: We evaluated all patients admitted to the Dana-
Farber Cancer Institute Bone Marrow Transplant PA service
(BMT-PA) for autologous SCT between June 1, 2012 and Aug
31st 2012.
Results: During the ﬁrst three month study period, 69
patients were admitted to the BMT-PA service. Of the
admissions, 11 (23%) had a CXR without indication. Seven
CXR were ordered by PAs and 4 were ordered by nocturnist.
Conclusions:While we did not reach our target of 10% in the
ﬁrst Plan-Do-Study-Act (PDSA) Cycle, wewere able to reduce
the number of unnecessary CXR in asymptomatic F+N SCT
patients by close to 50%. This reduction includes a cost
savings of approximately $23,000, as well as a reduction in
radiation exposure, overall resource utilization, time off
protected air ﬂow units and patient inconvenience. Our
second PDSA cycle will include a clinician perception analysis
to identify why clinicians may feel it is necessary to order
a CXR in asymptomatic SCT patients with F+N, despite the
nationally recognized guidelines. We will provide ongoing
education sessions and continue toward our aim of less
than 10%.160
The Family Experience Following Bone Marrow/Blood Cell
Transplantation
Linda Karen Young. College of Nursing and Health Sciences,
University of Wisconsin- Eau Claire, Eau Claire, WI
Aim: This is a report of a study which explored how families
with children at home managed four to 12 months after an
adult family member was discharged from the hospital
following bone marrow/blood cell transplantation.
Methods: This study was a descriptive, qualitative, one-
point-in-time study. Content analysis in relation to the three
conceptual components of the Family Management Style
Framework was employed; inductive thematic analysis
determined the emergent conceptual dimensions present in
the data.
Results/Findings: The three conceptual components of the
Family Management Style Framework, (1) deﬁnition of the
situation, (2) management behaviors and (3) perceived
consequences, were validated as relevant for this sample
across all participants. New conceptual dimensions were also
present, inclusive of: recovery view, support base, ﬁnancial
picture, management domains, perceived consequences to
the whole family and perceived consequences to the dyad
relationships.
Conclusion: Implications for nursing practice include
a better understanding of how adult patients and their
families manage during the recovery phase. Future research
should include use of The Family Management Style Frame-
work throughout the entire transplant experience.
